1. Home
  2. AMPH vs NVAX Comparison

AMPH vs NVAX Comparison

Compare AMPH & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amphastar Pharmaceuticals Inc.

AMPH

Amphastar Pharmaceuticals Inc.

HOLD

Current Price

$26.02

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$7.79

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPH
NVAX
Founded
1996
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2014
1995

Fundamental Metrics

Financial Performance
Metric
AMPH
NVAX
Price
$26.02
$7.79
Analyst Decision
Buy
Hold
Analyst Count
6
8
Target Price
$31.00
$9.75
AVG Volume (30 Days)
360.6K
3.9M
Earning Date
02-26-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
2.27
2.07
Revenue
$723,305,000.00
$1,064,651,000.00
Revenue This Year
$1.35
$58.91
Revenue Next Year
$5.10
N/A
P/E Ratio
$12.23
$3.96
Revenue Growth
N/A
20.27
52 Week Low
$20.39
$5.01
52 Week High
$39.01
$10.65

Technical Indicators

Market Signals
Indicator
AMPH
NVAX
Relative Strength Index (RSI) 44.32 59.40
Support Level $27.31 $7.15
Resistance Level $29.52 $8.81
Average True Range (ATR) 1.05 0.36
MACD -0.01 0.13
Stochastic Oscillator 4.53 57.61

Price Performance

Historical Comparison
AMPH
NVAX

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: